|
Oct 3
|
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
|
|
Oct 2
|
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
|
|
Sep 30
|
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
|
|
Jul 25
|
Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates
|
|
Jul 24
|
Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
|
|
Jun 27
|
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
|
|
Jun 27
|
Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
|
|
Jun 26
|
ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
|
|
Jun 26
|
Annovis Bio Files Patent for New Composition of Matter for Buntanetap
|
|
Jun 25
|
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
|
|
Jun 11
|
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
|
|
May 21
|
Annovis Announces New Publication in a Peer-Reviewed Journal
|
|
May 17
|
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
|
|
May 16
|
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
|
|
May 13
|
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
|
|
May 10
|
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
|
|
May 10
|
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
|
|
May 9
|
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
|
|
May 9
|
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
|
|
May 9
|
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
|